Hidetoshi Hayashi

13.3k total citations · 1 hit paper
248 papers, 5.2k citations indexed

About

Hidetoshi Hayashi is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Hidetoshi Hayashi has authored 248 papers receiving a total of 5.2k indexed citations (citations by other indexed papers that have themselves been cited), including 178 papers in Pulmonary and Respiratory Medicine, 177 papers in Oncology and 54 papers in Molecular Biology. Recurrent topics in Hidetoshi Hayashi's work include Lung Cancer Treatments and Mutations (156 papers), Lung Cancer Research Studies (72 papers) and Colorectal Cancer Treatments and Studies (45 papers). Hidetoshi Hayashi is often cited by papers focused on Lung Cancer Treatments and Mutations (156 papers), Lung Cancer Research Studies (72 papers) and Colorectal Cancer Treatments and Studies (45 papers). Hidetoshi Hayashi collaborates with scholars based in Japan, United States and South Korea. Hidetoshi Hayashi's co-authors include Kazuhiko Nakagawa, Masayuki Takeda, Kaoru Tanaka, Koji Haratani, Kazuto Nishio, Kimio Yonesaka, Yasutaka Chiba, Hiroyasu Kaneda, Ryoji Kato and Kazuko Sakai and has published in prestigious journals such as Journal of Clinical Investigation, Journal of Clinical Oncology and PLoS ONE.

In The Last Decade

Hidetoshi Hayashi

230 papers receiving 5.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non–Small-Cell Lung Cancer

2017 726 citations Koji Haratani, Hidetoshi Hayashi et al. profile →

Peers

Countries citing papers authored by Hidetoshi Hayashi

Since Specialization

Citations

This map shows the geographic impact of Hidetoshi Hayashi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hidetoshi Hayashi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hidetoshi Hayashi more than expected).

Fields of papers citing papers by Hidetoshi Hayashi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hidetoshi Hayashi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hidetoshi Hayashi. The network helps show where Hidetoshi Hayashi may publish in the future.

Co-authorship network of co-authors of Hidetoshi Hayashi

This figure shows the co-authorship network connecting the top 25 collaborators of Hidetoshi Hayashi. A scholar is included among the top collaborators of Hidetoshi Hayashi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hidetoshi Hayashi. Hidetoshi Hayashi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Myeloid Cells Induce Infiltration and Activation of B Cells and CD4+ T Follicular Helper Cells to Sensitize Brain Metastases to Combination Immunotherapy 2025 ·Cancer Research ·(unknown), (unknown), (unknown), Masaki Magari, (unknown), Youki Ueda, Takamasa Ishino, Joji Nagasaki, Tomohiro Fujiwara, Hidetaka Yamamoto, Hidetoshi Hayashi, Kota Tachibana, Joji Ishida, Yoshihiro Otani, (unknown), Shinichi Toyooka, Isamu Okamoto, Yosuke Togashi	2
2	Initial symptoms and diagnostic delay in immune checkpoint inhibitor-related adrenal insufficiency: a systematic review and meta-ethnography of case reports 2025 ·Frontiers in Endocrinology ·Ryuichi Ohta, Yoshinori Ryu, Kaoru Tanaka, Chiaki Sano, Hidetoshi Hayashi	0
3	Hemophagocytic lymphohistiocytosis induced by nivolumab/ipilimumab combination therapy: A case of lung adenocarcinoma that responded to early steroid pulse therapy 2024 ·Cancer Reports ·Satoru Hagiwara, Junko Tanizaki, Hidetoshi Hayashi, Yoriaki Komeda, Naoshi Nishida, Akihiro Yoshida, (unknown), (unknown), Masatoshi Kudo	1
4	Dual single‑nucleotide polymorphism biomarker combination for opioid selection to treat cancer pain 2024 ·Molecular and Clinical Oncology ·Yoshihiko Fujita, Hiromichi Matsuoka, Yasutaka Chiba, Junji Tsurutani, Takeshi Yoshida, (unknown), (unknown), (unknown), (unknown), (unknown), Kaoru Tanaka, Hidetoshi Hayashi, Takayuki Takahama, Junko Tanizaki, Atsuko Koyama, Kazuto Nishio, Kazuhiko Nakagawa	1
5	IDeate-Lung02: A phase 3, randomized, open-label study of ifinatamab deruxtecan (I-DXd) vs treatment of physician’s choice (TPC) in relapsed small cell lung cancer (SCLC). 2024 ·Journal of Clinical Oncology ·Taofeek K. Owonikoko, Lauren A. Byers, Ying Cheng, Hidetoshi Hayashi, Luis Paz‐Ares, M. Pérol, Jennifer Turner, Meng Qian, (unknown), (unknown), Charles M. Rudin	8
6	Targeting ErbB and tankyrase1/2 prevent the emergence of drug-tolerant persister cells in ALK-positive lung cancer 2024 ·npj Precision Oncology ·(unknown), Koh Furugaki, (unknown), Satoshi Muraoka, Makoto Nishio, Jun Adachi, Ken Uchibori, Eisaku Miyauchi, Hidetoshi Hayashi, Ryohei Katayama, (unknown)	4
7	510MO Trastuzumab deruxtecan (T-DXd) in Asian patients (Pts) with human epidermal growth factor receptor 2 (HER2; ERBB2)-mutant (HER2m) metastatic non-small cell lung cancer (mNSCLC): Subgroup analysis of DESTINY–Lung02 (DL-02) 2023 ·Annals of Oncology ·Yasushi Goto, Kōichi Goto, Toshio Kubo, Kiichiro Ninomiya, S-W. Kim, M-J. Ahn, Kazuhiko Nakagawa, Hidetoshi Hayashi, Junichi Shimizu, Dongwook Kim, (unknown), (unknown), K.H. Lee, (unknown), Kaline Pereira, Ayumi Taguchi, Ahmed Ali, (unknown), (unknown), Pasi A. Jänne	2
8	1358P Safety of tepotinib + EGFR TKI (osimertinib or gefitinib) in patients with EGFRm NSCLC 2023 ·Annals of Oncology ·Ernest Nadal, (unknown), Valentina Guarneri, (unknown), (unknown), Marie Wislez, Cheng Huang, Chong Kin Liam, Julien Mazières, Lye Mun Tho, Hidetoshi Hayashi, Nguyen Viet Nhung, Puey Ling Chia, Filippo de Marinis, (unknown), Svenja Adrian, Barbara Ellers‐Lenz, Karin Berghoff, Niki Karachaliou, Yi‐Long Wu	1
9	MA13.10 Trastuzumab Deruxtecan in Patients with HER2-Mutant Metastatic Non-Small Cell Lung Cancer: Primary Results of DESTINY-Lung02 2023 ·Journal of Thoracic Oncology ·Pasi A. Jänne, Yasushi Goto, Toshio Kubo, Kiichiro Ninomiya, (unknown), (unknown), Myung‐Ju Ahn, Egbert F. Smit, Adrianus J. de Langen, M. Pérol, (unknown), Silvia Novello, Hidetoshi Hayashi, Junichi Shimizu, D.-W. Kim, (unknown), Fang Cheng, Ayumi Taguchi, Yun Cheng, Kōichi Goto	2
10	552P TROPION-Lung05: Datopotamab deruxtecan (Dato-DXd) in Asian patients (pts) with previously treated non-small cell lung cancer (NSCLC) with actionable genomic alterations (AGAs) 2023 ·Annals of Oncology ·M-J. Ahn, Byoung Chul Cho, Yasushi Goto, Kiyotaka Yoh, Wu‐Chou Su, Junichi Shimizu, Jin Sun Lee, Satoshi Oizumi, (unknown), Hidetoshi Hayashi, Hong Zebger‐Gong, (unknown), Lei Lan, (unknown), Satoru Kitazono	4
11	Nivolumab Retreatment in Non–Small Cell Lung Cancer Patients Who Responded to Prior Immune Checkpoint Inhibitors and Had ICI-Free Intervals (WJOG9616L) 2022 ·Clinical Cancer Research ·Hiroaki Akamatsu, Shunsuke Teraoka, Shinkichi Takamori, Satoru Miura, Hidetoshi Hayashi, Akito Hata, Yukihiro Toi, Yoshimasa Shiraishi, Nobuaki Mamesaya, Yuki Sato, Naoki Furuya, Jun Oyanagi, Yasuhiro Koh, Toshihiro Misumi, Nobuyuki Yamamoto, Kazuhiko Nakagawa	22
12	KRAS Inhibitor Resistance in MET -Amplified KRAS G12C Non–Small Cell Lung Cancer Induced By RAS- and Non–RAS-Mediated Cell Signaling Mechanisms 2021 ·Clinical Cancer Research ·Shinichiro Suzuki, Kimio Yonesaka, Takeshi Teramura, Toshiyuki Takehara, Ryoji Kato, Hitomi Sakai, Koji Haratani, Junko Tanizaki, Hisato Kawakami, Hidetoshi Hayashi, Kazuko Sakai, Kazuto Nishio, Kazuhiko Nakagawa	66
13	Impact of EGFR-TKI Treatment on the Tumor Immune Microenvironment in EGFR Mutation–Positive Non–Small Cell Lung Cancer 2020 ·Clinical Cancer Research ·(unknown), Koji Haratani, Hidetoshi Hayashi, Shigeki Shimizu, Shuta Tomida, Takashi Niwa, Toshihide Yokoyama, Yasushi Fukuda, Yasutaka Chiba, Ryoji Kato, Junko Tanizaki, Kaoru Tanaka, Masayuki Takeda, Takashi Ogura, Tadashi Ishida, Akihiko Ito, Kazuhiko Nakagawa	172
14	Afatinib against Esophageal or Head-and-Neck Squamous Cell Carcinoma: Significance of Activating Oncogenic HER4 Mutations in HNSCC 2016 ·Molecular Cancer Therapeutics ·Yu Nakamura, Yosuke Togashi, Hirokazu Nakahara, Shuta Tomida, Eri Banno, Masato Terashima, Hidetoshi Hayashi, Marco A. De Velasco, Kazuko Sakai, Yoshihiko Fujita, Takatsugu Okegawa, Kikuo Nutahara, Suguru Hamada, Kazuto Nishio	13
15	Functional Analyses of Mutations in Receptor Tyrosine Kinase Genes in Non–Small Cell Lung Cancer: Double-Edged Sword of DDR2 2016 ·Clinical Cancer Research ·Masato Terashima, Yosuke Togashi, Katsuaki Sato, Hiroshi Mizuuchi, Kazuko Sakai, Kenichi Suda, Yu Nakamura, Eri Banno, Hidetoshi Hayashi, Marco A. De Velasco, Yoshihiko Fujita, Shuta Tomida, Tetsuya Mitsudomi, Kazuto Nishio	15
16	MEK Inhibitor for Gastric Cancer with MEK1 Gene Mutations 2014 ·Molecular Cancer Therapeutics ·Shunsuke Sogabe, Yosuke Togashi, Hiroaki Kato, (unknown), Takuro Mizukami, Yoichi Sakamoto, Eri Banno, Masato Terashima, Hidetoshi Hayashi, Marco A. De Velasco, Kazuko Sakai, Yoshihiko Fujita, Shuta Tomida, Takushi Yasuda, Yoshifumi Takeyama, Kiyotaka Okuno, Kazuto Nishio	16
17	Activation of HER Family Signaling as a Mechanism of Acquired Resistance to ALK Inhibitors in EML4-ALK–Positive Non–Small Cell Lung Cancer 2012 ·Clinical Cancer Research ·Junko Tanizaki, Isamu Okamoto, Takafumi Okabe, Kazuko Sakai, Kaoru Tanaka, Hidetoshi Hayashi, Hiroyasu Kaneda, Ken Takezawa, Kiyoko Kuwata, Haruka Yamaguchi, Erina Hatashita, Kazuto Nishio, Kazuhiko Nakagawa	126
18	Giant Tumor of Parotid Gland; A Case Report. 1993 ·Practica Oto-Rhino-Laryngologica ·Masahiko Hattori, Yukiyoshi Hamaguchi, Hidetoshi Hayashi, (unknown)	2
19	Nine cases of epiglottal cyst. 1987 ·Practica Oto-Rhino-Laryngologica ·(unknown), Kazuhiko Takeuchi, Hidetoshi Hayashi, Yuichi Majima, Kotaro Ukai, Yasuo Sakakura	1
20	[In vitro sensitivity test of anti-neoplastic agents and their enhancement by biscoclaurine alkaloid]. 1985 ·PubMed ·S Sekiya, Muneto Mogi, (unknown), Hidetoshi Hayashi, Takeo UCHIYAMA, (unknown)	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact